10-K: Spectral AI, Inc. Files 10-K Report, Highlights Progress in AI-Driven Medical Diagnostics

Spectral AI, Inc. released its 2023 annual report, detailing advancements in its DeepView System and financial performance, including significant government funding and regulatory milestones.

Summary

• Spectral AI, Inc., an AI company focused on predictive medical diagnostics, filed its annual report on Form 10-K for the year ended December 31, 2023.
• The company's DeepView System uses AI algorithms to assess wound healing potential, with a focus on burn and diabetic foot ulcer (DFU) indications.
• Spectral AI received approximately $279.6 million in government funding since 2013, with $272.9 million from BARDA.
• A new BARDA contract was executed on September 27, 2023, providing up to $150 million in additional funding, including an initial award of $54.9 million.
• The DeepView System received UKCA marking for burn indications on February 22, 2024, with full registration completed on March 7, 2024.
• The company anticipates a Class II medical device designation from the FDA via a De Novo application.
• The DeepView System's AI model is trained and tested against a database of approximately 340 billion pixels of DFU and burn data as of December 31, 2023.
• The company incurred a net loss of $20.9 million in 2023 and had an accumulated deficit of $32.8 million as of December 31, 2023.
• As of March 25, 2024, there were 17,466,871 shares of Common Stock issued and outstanding.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments in technology and regulatory approvals, the company's financial losses and dependence on government funding raise concerns. The potential for future capital raises also adds uncertainty.

Positives

• The DeepView System has shown high accuracy in clinical trials for both burn and DFU wound assessment.
• The company has secured significant non-dilutive funding from government contracts, particularly from BARDA.
• The company has a large proprietary database of wound data, creating a barrier to entry for competitors.
• The company has strategic partnerships with leading medical institutions and healthcare providers.
• The company has a strong intellectual property portfolio with multiple patents and trademarks.
• The company has a experienced management team with a track record of success in the technology and healthcare sectors.

Negatives

• The company has incurred significant losses since inception and may not achieve profitability.
• The company is highly dependent on government funding, particularly from BARDA.
• The regulatory review process is expensive, time-consuming, and uncertain.
• The company may experience delays in completing clinical trials.
• The company has no experience in marketing and selling its DeepView System.
• The company is dependent on third-party suppliers, including contract manufacturers and single and sole source suppliers.

Risks

• The company may not be able to achieve significant revenues or profitability.
• The company's BARDA contract is not guaranteed to be extended.
• The company may experience significant delays in completing clinical trials.
• The company may be unable to obtain regulatory clearance, approval, or certification for its DeepView technology.
• The company may face competition from larger companies with more resources.
• The company may encounter difficulties in managing its growth.
• The company is highly dependent on its senior management and key personnel.
• The company's use of artificial intelligence may result in reputational harm or liability.
• The company may be subject to product liability suits.
• The company may be unable to maintain proper and effective internal controls over financial reporting.
• The company's securities may be delisted from Nasdaq.
• The company may need additional funding to finance its planned operations and may not be able to raise capital when needed.

Future Outlook

The company intends to commercialize the DeepView System in the US and UK, targeting initial sales in the UK in the second half of 2024, and expects to submit a De Novo application to the FDA for market authorization of the burn application in early 2025.

Management Comments

• The company believes that its grant funding is non-dilutive to its stockholders and validates the important nature of its mission and technology.
• The company intends to initially sell the DeepView System throughout the United States and the UK for its burn and its DFU indication.
• The company plans to target sales efforts to burn centers, trauma centers, and emergency rooms through a highly-trained technical sales support staff.
• The company plans to engage contract sales organizations to distribute its DeepView System throughout the UK and eventually in the EU4.

Industry Context

The announcement highlights Spectral AI's position in the growing market for AI-driven medical diagnostics, particularly in wound care. The company's focus on predictive analytics and objective assessments differentiates it from traditional methods that rely on subjective clinician opinions. The company is competing with companies that have developed wound imaging systems for burn injuries and DFUs; however, these systems incorporate technology such as spatial frequency domain imaging, thermal imaging, photographic documentation, hyperspectral imaging, and near-infrared imaging that provide physiologic data to the physician. Ultimately, this physiologic data appears to only provide an indirect linkage to wound healing and does not display a binary result of healing vs. non-healing.

Comparison to Industry Standards

• The DeepView System's 92% accuracy in identifying non-healing burn regions in adults is significantly higher than the 50-75% accuracy reported for burn physicians in industry literature.
• The DeepView System's 86% accuracy in predicting DFU wound healing potential is also higher than the 50% accuracy reported for current physician assessments.
• The company's technology is unique in that it provides a binary result of healing vs. non-healing, unlike other wound imaging systems that provide only physiologic data.
• The company's proprietary database of 340 billion pixels of DFU and burn data is a significant barrier to entry for competitors.
• The company's technology is designed to provide a Day One assessment of a wound's healing potential, which is a significant improvement over current methods that rely on a wait-and-see approach.

Stakeholder Impact

• Shareholders may experience dilution due to potential capital raises.
• Employees may benefit from the company's growth and potential commercial success.
• Customers (healthcare providers) may benefit from the DeepView System's improved diagnostic capabilities.
• Suppliers and contract manufacturers may benefit from increased demand for the company's products.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to fulfill contractual obligations under the BARDA PBS contract.
• The company will pursue commercialization of the DFU application in the UK, United States, and EU4.
• The company will submit a De Novo application to the FDA for market authorization of the burn application in early 2025.
• The company will continue to develop the DFU AI model and complete validation studies for regulatory applications.
• The company will continue to expand its sales, marketing, and distribution capabilities.

Key Dates

Keywords

AI, medical diagnostics, DeepView System, wound care, burns, diabetic foot ulcers, BARDA, FDA, UKCA, clinical trials, artificial intelligence, machine learning, regulatory approval, government funding, intellectual property